- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Entera Bio Ltd (ENTX)
Track today's live Entera Bio (ENTX) share price, performance and key data on this page with our current NASDAQ:ENTX stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Entera Bio share price on the NASDAQ exchange. Use the dropdown to switch exchange for the ENTX share price, head to our technical summary section, which provides analysis on Entera Bio share price buy/sell indicators using real-time data (or discuss the Entera Bio (ENTX) stock price today with other investors in the Entera Bio NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:ENTX share price (ISIN: IL0011429839) to enhance your trading decisions with our free investment tools and resources.
What Is the Entera Bio Ltd Share Price Today?
The Entera Bio share price today is 2.840.
What Is the Stock Symbol for Entera Bio Ltd
The stock symbol (or 'ticker') for Entera Bio Ltd is "ENTX."
What Stock Exchange Does Entera Bio Ltd Trade On?
Entera Bio Ltd is listed and trades on the NASDAQ stock exchange.
Is Entera Bio Ltd a Good Stock to Buy?
Determining whether Entera Bio (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:ENTX share price (ISIN: IL0011429839) to enhance your trading decisions with our free investment tools and resources.
What Is the Entera Bio Ltd Share Price Today?
The Entera Bio share price today is 2.840.
What Is the Stock Symbol for Entera Bio Ltd
The stock symbol (or 'ticker') for Entera Bio Ltd is "ENTX."
What Stock Exchange Does Entera Bio Ltd Trade On?
Entera Bio Ltd is listed and trades on the NASDAQ stock exchange.
Is Entera Bio Ltd a Good Stock to Buy?
Determining whether Entera Bio (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.830
3.040
52 wk Range
0.910
4.200
ENTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.8303.040
52 wk Range
0.9104.200
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ENTX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
9.000
Upside
+216.90%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Entera Bio misses Q2 estimates, reports wider loss- Investing.com
Form 8K Entera Bio Ltd. For: 18 August- Investing.com
- Form 8K Entera Bio Ltd. For: 18 August
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 9.000
(+216.90% Upside)
Earnings
Latest Release
10/08/2026
EPS / Forecast
-0.14 / -0.09
Revenue / Forecast
-- / --
Compare ENTX to Peers and Sector
Metrics to compare | ENTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipENTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −28.9x | −2.5x | −0.4x | |
PEG Ratio | 0.78 | −0.04 | 0.00 | |
Price/Book | 67.7x | 3.0x | 2.6x | |
Price / LTM Sales | - | 24.2x | 3.0x | |
Upside (Analyst Target) | 199.0% | 757.1% | 51.3% | |
Fair Value Upside | Unlock | 21.4% | 7.8% | Unlock |
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Entera Bio (NASDAQ: ENTX) Share Price Today?
The Entera Bio stock price today is 2.840 USD.
What Stock Exchange Does Entera Bio (ENTX) Trade On?
Entera Bio is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Entera Bio?
The stock symbol (also called a 'ticker') for Entera Bio is "ENTX."
What Is the Current Entera Bio Market Capitalisation?
As of today, Entera Bio (NASDAQ: ENTX) market cap is 491.720M USD.
What Is Entera Bio's (ENTX) Earnings Per Share (TTM)?
The Entera Bio EPS is currently -0.354 (Trailing Twelve Months).
When Is the Next Entera Bio Earnings Date?
Entera Bio's next earnings report will be released on 05/11/2026.
Is ENTX a Buy or Sell From a Technical Analyst Perspective?
Based on today's Entera Bio moving averages and other technical indicators, the daily buy/sell signal for ENTX stock is Sell.
How Many Times Has Entera Bio Stock Split?
Entera Bio has split 0 times. (See the ENTX stock split history page for full effective split date and price information.)
How Many Employees Does Entera Bio Have?
Entera Bio has 21 employees, based on their latest Companies House report.
What is the current trading status of Entera Bio (NASDAQ: ENTX)?
As of 10/09/2026, Entera Bio (ENTX) is trading at a share price of 2.840 USD, with a previous close of 2.840 USD. The stock has fluctuated within a day range of 2.830 USD to 3.040 USD, while its 52-week range spans from 0.910 USD to 4.200 USD.
What Is Entera Bio (ENTX) Price Target According to Analysts?
The average 12-month price target for Entera Bio is 9.000 USD, with a high estimate of 9 USD and a low estimate of 9 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +216.90% Upside potential.
What Is the ENTX Premarket Price?
ENTX's last pre-market stock price is 2.710 USD. The pre-market share volume is 10.000, and the stock has decreased by -0.130, or -4.580%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.